Literature DB >> 20831527

Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

R B Raffa1, R J Tallarida.   

Abstract

The diminution in certain aspects of cognitive function that is reported to occur in some patients during or after adjuvant cancer chemotherapy is variously known as 'chemo-fog', 'chemo-brain' or other such term. In addition to reported deficits in attention, concentration and other functions, most, if not all, of the studies report deficits involving visual-spatial function or visual memory. Since the visual system is part of the nervous system, it seems reasonable to ask if it is susceptible to some of the deleterious effects produced by adjuvant chemotherapeutic drugs. We propose here the possibility that some portion of the vision-related aspects of the 'chemo-fog' spectrum of cognitive deficits results from a direct action of the adjuvant drugs on the visual system or from drug/drug or site/site interaction between effects on the visual system and other critical brain regions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831527      PMCID: PMC3249620          DOI: 10.1111/j.1365-2710.2009.01086.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  39 in total

1.  An overview of drug combination analysis with isobolograms.

Authors:  Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2006-05-02       Impact factor: 4.030

Review 2.  Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?

Authors:  R B Raffa; P V Duong; J Finney; D A Garber; L M Lam; S S Mathew; N N Patel; K C Plaskett; M Shah; H-F Jen Weng
Journal:  J Clin Pharm Ther       Date:  2006-04       Impact factor: 2.512

Review 3.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

Review 4.  Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Authors:  G Pentheroudakis; E Razis; A Athanassiadis; N Pavlidis; G Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

5.  On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Authors:  Adam J Shuhendler; Peter J O'Brien; Andrew M Rauth; Xiao Yu Wu
Journal:  Drug Metabol Drug Interact       Date:  2007

6.  Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol).

Authors:  R B Raffa; D J Stone; R J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 7.  Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer.

Authors:  A Stevens; D Spooner
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

8.  Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

Authors:  C B Brezden; K A Phillips; M Abdolell; T Bunston; I F Tannock
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 9.  Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy.

Authors:  S Prasad; G G Kamath; R P Phillips
Journal:  Acta Ophthalmol Scand       Date:  2000-02

10.  Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Int J Oncol       Date:  2008-10       Impact factor: 5.650

View more
  12 in total

Review 1.  Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2010-08-24       Impact factor: 2.512

2.  A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog').

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2010-08-24       Impact factor: 2.512

Review 3.  Engaging neuroscience to advance translational research in brain barrier biology.

Authors:  Edward A Neuwelt; Björn Bauer; Christoph Fahlke; Gert Fricker; Constantino Iadecola; Damir Janigro; Luc Leybaert; Zoltán Molnár; Martha E O'Donnell; John T Povlishock; Norman R Saunders; Frank Sharp; Danica Stanimirovic; Ryan J Watts; Lester R Drewes
Journal:  Nat Rev Neurosci       Date:  2011-03       Impact factor: 34.870

Review 4.  The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.

Authors:  Lauren E Abrey
Journal:  J Neurooncol       Date:  2012-02-17       Impact factor: 4.130

5.  COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67.

Authors:  Wen Li; Sheng Yu; Xu Duan; Senbang Yao; Lingxue Tang; Huaidong Cheng
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

6.  Episodic memory for visual scenes suggests compensatory brain activity in breast cancer patients: a prospective longitudinal fMRI study.

Authors:  Denise Pergolizzi; James C Root; Hong Pan; David Silbersweig; Emily Stern; Steven D Passik; Tim A Ahles
Journal:  Brain Imaging Behav       Date:  2019-12       Impact factor: 3.978

Review 7.  Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research.

Authors:  David E Anderson; Sarah A Holstein; Sachin Kedar
Journal:  Neuroophthalmology       Date:  2020-01-06

8.  Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study.

Authors:  David E Anderson; Sachin Kedar; Vijaya R Bhatt; Kendra Schmid; Sarah A Holstein; Matthew Rizzo
Journal:  J Neurol Sci       Date:  2019-12-24       Impact factor: 3.181

Review 9.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

10.  Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study.

Authors:  Carole Scherling; Barbara Collins; Joyce Mackenzie; Catherine Bielajew; Andra Smith
Journal:  Front Hum Neurosci       Date:  2011-11-01       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.